About this book
Fabry disease is an X-linked inborn error of metabolism wherein deficiency
of a lysosomal enzyme results in systemic deposition of glycosphingolipids.
Storage deposition, and hence pathological disease, occurs preferentially in
renal glomerular and tubular epithelial cells, myocardial cells, heart valve
fibrocytes, neurons of dorsal root ganglia, and in endothelial smooth muscle
cells of blood vessels. Thus, Fabry disease is a multi-system disorder, albeit
with considerable phenotypic heterogeneity in onset and in severity; however,
it is progressive, exhibits extensive morbidity, and is life-threatening. Within
the past two decades, there has been a radical change in the natural course
Fabry disease by virtue of the availability of specific enzyme replacement therapy.
Moreover, there has been a concerted effort to better understand the underlying
pathology and equally to identify patients prior to the onset of irreversible
end-organ damage. It is to be hoped that the future for patients with Fabry
disease can be viewed with greater, albeit guarded, optimism. This state-of-the-art
textbook attempts to bridge the span of pre-clinical studies, clinical finding,
and management options in a readable but comprehensive manner for the medical
practitioner as well as the interested non-medical reader.
Content Level » Research
Related subjects » Human Genetics - Internal Medicine
Table of Contents
Introduction.- Dedication page.- Fabry Disease – An Overview.- Fabry Disease – A patient perspective.- Part I Pre-Clinical.- 1. Molecular genetics of Fabry disease and genotype-phenotype correlation.- 2. The structure of human a-galactosidase A and implications for Fabry Disease.- 3. Subcellular, cellular and organ pathology of Fabry disease.- 4. Biochemistry of Fabry disease.- 5. Clinical relevant examples of genotype-phenotype correlation.- 6. Laboratory diagnosis of Fabry disease.- 7. Biomarkers for Fabry Disease.- 8. Fabry disease case finding studies in high-risk populations.- 9. Small Molecule Drug Discovery for Fabry Disease.- Part II Clinical.- 10. Clinical Manifestations of Fabry disease: an overview.- 11. The Heart in Fabry Disease – from Pathogenesis to Enzyme Replacement Therapy.- 12. Renal manifestations of Fabry Disease.- 13. Neurological manifestations in Fabry Disease.- 14. Dermatological manifestations of Fabry Disease.- 15. Histopathology of skin in Fabry Disease.- 16. Bone and muscle involvement in Fabry Disease.- 17. The eye in Fabry Disease.- 18. Pulmonary, ear and less commonly appreciated manifestations.- 19. Neuropsychiatric manifestations of Anderson-Fabry disease.- 20. Genetic counseling and psychosocial issues for individuals and their families with Fabry Disease.- 21. Fabry Disease in Females.- 22. Fabry Disease in Pediatric patients.- 23. Experimental Studies in Mice on the Vasculopathy of Fabry Disease.- Part III Management.- 24. Overview.- 25. Agalsidase alfa in the treatment of Anderson-Fabry Disease.- 26. Agalsidase beta clinical trials and long-term experience.- 27. Analyses of Agalsidase Alfa and Agalsidase Beta for the Treatment of Fabry Disease.- 28. Enzyme therapy in children.- 29. Pharmacological Chaperone Therapy for Fabry Disease.- 30. Potential factors influencing treatment outcomes.- 31. Symptomatic and ancillary therapy.- 32. The Price of Cars vs the Cost of Caring.- Summary Fabry Disease, a uniquely different lysosomal storage disorders.- List of Patient Associations around the world